NYSE:ABBVAbbVie Stock Price, Forecast & News

$90.13

-0.91 (-1.00 %)

(As of 06/3/2020 11:55 AM ET)

Add

Compare

Today's Range

$89.60

Now: $90.13▼

$91.50

50-Day Range

$79.75

MA: $86.48▼

$93.02

52-Week Range

$62.55

Now: $90.13▼

$97.86

Volume3.10 million shs

Average Volume13.10 million shs

Market Capitalization$133.10 billion

P/E Ratio15.95

Dividend Yield5.20%

Beta0.85

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; and Calico Life Sciences LLC. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
AbbVie has received a consensus rating of Buy. The company's average rating score is 2.79, and is based on 11 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $101.31, AbbVie has a potential upside of 12.5% from its current price of $90.06.
Amount of Analyst Coverage
AbbVie has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.9 Community Rank

Outperform Votes
AbbVie has received 1,168 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
AbbVie has received 833 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
AbbVie has received 58.37% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote “Outperform” if you believe ABBV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ABBV will underperform the S&P 500 over the long term. You may vote once every thirty days.

5.0 Dividend Strength

Dividend Leadership
AbbVie is a leading dividend payer. It pays a dividend yield of 5.20%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
AbbVie has been increasing its dividend for 47 years.
Dividend Coverage
The dividend payout ratio of AbbVie is 52.80 %. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, AbbVie will have a dividend payout ratio of 39.24 % next year. This indicates that AbbVie will be able to sustain or increase its dividend.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AbbVie insiders have sold 454.44% more of their company's stock than they have bought. Specifically, they have bought $671,852.00 in company stock and sold $3,724,985.00 in company stock.
Percentage Held by Insiders
Only 0.09% of the stock of AbbVie is held by insiders.
Percentage Held by Institutions
72.44% of the stock of AbbVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for AbbVie are expected to grow by 12.43% in the coming year, from $10.70 to $12.03 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AbbVie is 15.94, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 15.96.
Price to Earnings Ratio vs. Sector
The P/E ratio of AbbVie is 15.94, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.43.
Price to Earnings Growth Ratio
AbbVie has a PEG Ratio of 1.92. PEG Ratios above 1 indicate that a company could be overvalued.

Overall Beat the Market Rank^™

2.83 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

Current SymbolNYSE:ABBV

Previous Symbol

CUSIP00287Y10

CIK1551152

Webwww.abbvie.com

Phone847-932-7900

Debt

Debt-to-Equity RatioN/A

Current Ratio3.14

Quick Ratio3.03

Price-To-Earnings

Trailing P/E Ratio15.95

Forward P/E Ratio8.42

P/E Growth1.92

Sales & Book Value

Annual Sales$33.27 billion

Price / Sales4.00

Cash Flow$10.27 per share

Price / Cash Flow8.78

Book Value($5.53) per share

Price / Book-16.30

Profitability

EPS (Most Recent Fiscal Year)$8.94

Net Income$7.88 billion

Net Margins24.77%

Return on Equity-169.80%

Return on Assets18.52%

Miscellaneous

Employees30,000

Outstanding Shares1,476,740,000

Market Cap$133.10 billion

Next Earnings Date7/24/2020 (Estimated)

OptionableOptionable

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

AbbVie (NYSE:ABBV) Frequently Asked Questions

How has AbbVie's stock been impacted by COVID-19 (Coronavirus)?

AbbVie's stock was trading at $84.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ABBV shares have increased by 6.1% and is now trading at $90.06. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AbbVie?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AbbVie.

When is AbbVie's next earnings date?

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, July 24th 2020. View our earnings forecast for AbbVie.

How were AbbVie's earnings last quarter?

AbbVie Inc (NYSE:ABBV) announced its earnings results on Friday, May, 1st. The company reported $2.42 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $2.25 by $0.17. The firm earned $8.62 billion during the quarter, compared to analysts' expectations of $8.31 billion. AbbVie had a negative return on equity of 169.80% and a net margin of 24.77%. AbbVie's revenue was up 10.1% compared to the same quarter last year. During the same quarter last year, the firm posted $2.14 EPS. View AbbVie's earnings history.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a quarterly dividend on Thursday, February 20th. Investors of record on Wednesday, April 15th will be paid a dividend of $1.18 per share on Friday, May 15th. This represents a $4.72 dividend on an annualized basis and a yield of 5.24%. The ex-dividend date is Tuesday, April 14th. View AbbVie's dividend history.

How will AbbVie's stock buyback program work?

AbbVie announced that its board has initiated a stock repurchase plan on Thursday, December 13th 2018, which permits the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 3.8% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company's board believes its shares are undervalued.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its FY 2020 After-Hours earnings guidance on Friday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $50-50 billion.

What price target have analysts set for ABBV?

14 Wall Street analysts have issued twelve-month price targets for AbbVie's stock. Their forecasts range from $90.00 to $122.00. On average, they expect AbbVie's share price to reach $101.31 in the next year. This suggests a possible upside of 12.5% from the stock's current price. View analysts' price targets for AbbVie.

Has AbbVie been receiving favorable news coverage?

Headlines about ABBV stock have been trending neutral recently, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AbbVie earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutAbbVie.

Who are some of AbbVie's key competitors?

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Zogenix (ZGNX) and Corcept Therapeutics (CORT). View all competitors.

What other stocks do shareholders of AbbVie own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX), Bristol-Myers Squibb (BMY) and Valeant Pharmaceuticals Intl (VRX).

Who are AbbVie's key executives?

AbbVie's management team includes the following people:

Mr. Richard A. Gonzalez, Chairman & CEO (Age 65)
Dr. Michael E. Severino, Vice Chairman & Pres (Age 53)
Mr. Robert A. Michael, Sr. VP & CFO (Age 49)
Mr. William J. Chase, Exec. VP of Fin. & Admin. (Age 51)
Ms. Laura J. Schumacher, Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. (Age 56)

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.87%), State Street Corp (4.62%), Capital Research Global Investors (3.33%), Geode Capital Management LLC (1.75%), Bank of New York Mellon Corp (1.26%) and Janus Henderson Group PLC (0.78%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Roxanne S Austin, Timothy J Richmond and William J Chase. View institutional ownership trends for AbbVie.

Which institutional investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Two Sigma Advisers LP, Capital International Investors, Los Angeles Capital Management & Equity Research Inc., Invesco Ltd., American International Group Inc., Vaughan Nelson Investment Management L.P., and MERIAN GLOBAL INVESTORS UK Ltd. Company insiders that have sold AbbVie company stock in the last year include Jeffrey Ryan Stewart, and Timothy J Richmond. View insider buying and selling activity for AbbVie.

Which institutional investors are buying AbbVie stock?

ABBV stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Bank of New York Mellon Corp, BlackRock Inc., Advisor Group Holdings Inc., Geode Capital Management LLC, AQR Capital Management LLC, Bahl & Gaynor Inc., and Camber Capital Management LP. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin, and William J Chase. View insider buying and selling activity for AbbVie.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $90.06.

How big of a company is AbbVie?

AbbVie has a market capitalization of $133.00 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.

What is AbbVie's official website?

The official website for AbbVie is www.abbvie.com.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.

This page was last updated on 6/3/2020 by MarketBeat.com Staff